Tilray Brands (TLRY)
(Delayed Data from NSDQ)
$1.80 USD
-0.01 (-0.55%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $1.79 -0.01 (-0.56%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Tilray Brands, Inc. [TLRY]
Reports for Purchase
Showing records 1 - 20 ( 223 total )
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Tilray to Buy Four Craft Brands from Molson Coors
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Upside Derived From Hard-to-Handicap Legislative/Market Structure Outcomes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Cannabis Industry Update: German Adult-Use Passes, Medical Cannabis to Flourish
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Guidance Requires Heavy Lifting Ahead
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Predictions for 2024 - Through Our Beer/Wine/Spirits Goggles
Provider: Roth Capital Partners, Inc.
Analyst: KIRK W
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Core Soft Ahead of Transformative Deals
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Weekly ReHash: Monumental ReScheduling Signals U.S. Cannabis Normalization
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S